Ravi Ramana, DO
Interventional Cardiology · Palos Park, ILNPI 1679778716
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $345,257 of the $458,091 with a category attached, or 75.4%. Boston Scientific accounts for 62.8% of it on its own, with 41 other manufacturers making up the rest. Reporting peaked in 2021 at $106,256 and has fallen 70.4% since, to $31,460 in 2025. Among interventional cardiology clinicians in IL with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 768 payments — averaging $596.47 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Boston Scientific$288K
- Abbott$60K
- Medtronic$41K
- Cardiva Medical, Inc.$31K
- Cathworks, Inc.$12K
- Edwards Lifesciences$10K
- plus $16K from 36 others
Across 192 payments — averaging $12,450 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Boston Scientific$1.4M
- Edwards Lifesciences$363K
- Medtronic$344K
- Abbott$231K
- M.a. Med Alliance S.A.$24K
What the payments were for
- Consulting fees$345,25775%
- Speaking & faculty fees$69,21315%
- Travel & lodging$20,0184%
- Food & beverage$23,5555%
- Education$140%
- Entertainment$350%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- CLINICAL TRIAL PRODUCT$152,651
- SavvyWire$42,950
- Portico Transcatheter Aortic HV$26,563
- CoreValve Evolut$22,351
- Portico Transcatheter Aortic Heart Valve$13,188
- FFRangio$12,000
- Sentinel$9,875
- VANTAGEVIEW$6,163
- COREVALVE EVOLUT R$5,948
- Paradise Ultrasound Renal Denervation System$4,133
- FlexAbility Ablation Catheter$3,645
- Mitra Clip system$3,422
- GENERAL - STRUCTURAL HEART$3,000
- JenaValve Pericardial TAVR System$2,860
- CardioMEMS HF System$2,228
- Edwards SAPIEN 3 Transcatheter Heart Valve$2,177
- ACUSON SC2000 Diagnostic Ultrasound System$2,088
- GENERAL - THERAPIES$1,846
- WATCHMAN Access System$1,500
- VantageView System$1,488
How this compares
$458,091 in reported general payments places this provider in the 95th percentile of 303 interventional cardiology providers in Illinois.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 101 | $154,096 |
| BrilintaTicagrelor | 44 | $40,726 |
| XareltoRivaroxaban | 30 | $38,184 |
| EntrestoSacubitril/Valsartan | 27 | $32,214 |
| NexletolBempedoic Acid | 16 | $10,694 |
| Atorvastatin Calcium | 361 | $4,181 |
| ClopidogrelClopidogrel Bisulfate | 277 | $3,515 |
| Metoprolol Succinate | 187 | $3,176 |
| Metoprolol Tartrate | 363 | $2,739 |
| Rosuvastatin Calcium | 180 | $2,526 |
| Losartan Potassium | 131 | $1,343 |
| Amlodipine Besylate | 136 | $1,332 |
| Lisinopril | 146 | $1,330 |
| Furosemide | 184 | $1,028 |
| Prasugrel Hcl | 21 | $865 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $289 | $154,096101 claims |
| AstraZenecaBrilinta | $96 | $40,72644 claims |
| Johnson & JohnsonXarelto | $149 | $38,18430 claims |
| NovartisEntresto | $286 | $32,21427 claims |
| Esperion Therapeutics, Inc.Nexletol | $167 | $10,69416 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 303 interventional cardiology providers in Illinois.
Other interventional cardiology in Palos Park
- Hong Jun YunPalos Park$89K
- Andrei PopElk Grove Village$900K
- Atman ShahChicago$788K
- Mahesh RajuDowners Grove$281K
- Mark RicciardiEvanston$253K
- Neal SawlaniPark Ridge$246K
- Tony de MartiniSpringfield$208K
- Bouyella ReddyMoline$172K
- David StewartChicago$169K
- Jaafer GolzarOak Lawn$152K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.